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To examine how Jiang-Zhi-Ning (JZN) regulates cholesterol metabolism and compare the role of its four main components.
We established a beagle model of hyperlipidemia, fed with JZN extract and collected JZN-containing serum 0, 1, 2, 4, and 6h
later. Human liver cells Bel-7402 were stimulated with 10% JZN-containing serum as well as the four main components of
JZN and Atorvastatin. The mRNA expression of LDL receptor (LDL-R), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-
CoAR), cytochrome P450 7A1 (CYP7A1), and acetyl-Coenzyme A acetyltransferase 2 (ACAT2) was measured by real-time PCR.
LDL-R surface expression and LDL-binding and internalization were examined by ﬂow cytometry. The results showed that
JZN-containing serum signiﬁcantly increased the mRNA expression of LDL-R, HMG-CoAR, and CYP7A1 in Bel-7402 cells.
All the four components signiﬁcantly increased the mRNA and protein expression of LDL-R and HMG-CoAR and decreased
the mRNA and protein expression of ACAT2 in Bel-7402 cells. Hyperinand chrysophanol also markedly increased the mRNA
expression of CYP7A1. Stimulation with stilbene glycosidesigniﬁcantly increased the surface expression of LDL-R and the binding
and internalization of LDL. In conclusion, JZN and its four components have close relationship with the process of cholesterol
metabolism, emphasizing their promising application as new drug candidates in the treatment of hyperlipidemia.
1.Introduction
Numerous studies have shown that cholesterol plays a key
role in the development of atherosclerosis, which is the main
pathological basis of cardiovascular diseases [1]. Increase in
the level of serum total cholesterol, especially low-density
lipoprotein (LDL) cholesterol, is of signiﬁcant importance
in developing diseases. Multiple clinical experiments have
shown that lowering the level of serum total cholesterol,
especially LDL cholesterol, can decrease lipid content in
atherosclerotic plaques, lessen the shear force from blood
on the cap of ﬁbrous tissues, and reduce the secretion of
proteases from foam cells that can hydrolyze extracellular
matrix. This progress can stabilize plaques or even reduce
their size, stop disease progression, and decrease cardiovas-
cular morbidity and mortality [2].
Cholesterol metabolism is a complicated homeostasis
involving multiple steps, including cholesterol absorption,
synthesis,conversion,andmodiﬁcation.LDLreceptor(LDL-
R)playsacriticalroleincholesterolabsorption.Intheserum,
cholesterol mainly exists in the form of cholesterol ester and
is carried and transported by lipoproteins, such as LDL,
apolipoproteinB100(ApoB100),andapolipoproteinE(Apo
E). LDL-R binds to these lipoproteins and internalizes them
into cells, providing lipids for cell proliferation and synthesis
ofsteroidhormonesandbilesalt.Theseanimalsmetabolized
7.1 pools of LDL-cholesterol (LDL-C) per day, and 79% of
thisdegradationtookplaceintheliver.Ofthistotalturnover,2 Evidence-Based Complementary and Alternative Medicine
the LDLR accounted for 88% while the remaining 12%
was receptor independent. 91% of the receptor-dependent
transport identiﬁed in these animals was located in the liver
while only 38% of the receptor-independent uptake was
found in this organ [3]. Indeed, a functional deﬁcit in LDL-
R is one of the major causes of hypercholesterolemia and
atherosclerosis [4, 5].
Cholesterol in the body can be obtained from food
intake or from liver biosynthesis, the latter accounting for
generating 70% to 80% of serum total cholesterol [6]Thus,
inhibiting cholesterol biosynthesis is an eﬀective way to
reduce total cholesterol levels. Cholesterol synthesis includes
30 steps of enzymatic reaction, where 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG-CoAR) is a rate-limiting
enzyme. Currently available cholesterol-lowering drugs are
mainly statins, whose main target is HMG-CoAR.
Another important step in cholesterol metabolism is the
conversion of cholesterol into bile acid through cytochrome
P450-meidiated oxidation. The rate-limiting enzyme for
the dominant pathway of bile acid synthesis, the so-called
classic pathway, is cytochrome P450 7A1 (CYP7A1). Human
CYP7A1 gene defect can cause cholesterol accumulation
in the liver, which has been associated with hypercholes-
terolemia [7]. In contrast, high-level expression of CYP7A1
increases the mRNA expression of LDL-R in liver cells and
decreases the concentration of circulating LDL-cholesterol
even in LDL-R-deﬁcient mice [8]. In human, CYP7A1
expression is induced by its substrate cholesterol and inhib-
ited by negative feedback from bile acid [9].
Another interesting participant in cholesterol metabo-
lism is acetyl-CoA acetyltransferase 2 (ACAT2), which ester-
iﬁes cholesterol in the small intestine and liver. Cholesterol
esters synthesized by ACAT2 are packed into very-low-densi-
ty lipoprotein and secreted into blood. It is observed in
an atherosclerosis model of Apo E-deﬁcient mice that the
formation of atherosclerosis can be prevented by simultane-
ous knockout of ACAT2, suggesting that ACAT2-mediated
cholesterol esteriﬁcation is important for atherosclerosis
[10].
Among all current lipid-regulating drugs, Atorvastatin
shows the most signiﬁcant clinical eﬀects. Atorvastatin
decreases the cholesterol level by inhibiting HMG-CoAR
and promotes the transcription of LDL-R by activating the
transcriptionfactorsteroidresponseelementbindingprotein
2 (SREBP2). The deﬁned targets and marked lipid-lowering
eﬀects of Atorvastatin have made it a major breakthrough
in lipid-lowering drugs. Atorvastatin has now become a
preferred ﬁrst-line lipid-regulating drug. However, statins
may cause serious side reactions, such as liver toxicity
and statin myopathy, with symptoms including increases
in alanine aminotransferase and aspartate aminotransferase,
dermatomyositis and polymorphic myositis, and so forth. In
severe cases, statins can lead to rhabdomyolysis. Therefore,
it is imperative to develop novel, safe, and eﬀective lipid-
regulating drugs.
Traditional Chinese Medicine (TCM) has been used to
prevent and cure atherosclerosis and lower lipid for thou-
sands of years. Jiang-Zhi-Ning (JZN), a widely used ready-
made Chinese medicine, is composed of stilbene glycoside
(from ShouWu, ﬂeeceﬂower root), hyperin (from ShanZha,
fructus crataegi), nuciferine (from HeYe, folium nelumbi-
nis), and chrysophanol (from JueMingZi, semen cassiae).
JZN has been in clinical application for more than 1300 years
and has been shown to signiﬁcantly lower serum cholesterol
levels. The four herbs in JZN, Fleeceﬂower Root, Fructus
Crataegi, Folium Nelumbinis, and Semen Cassiae have been
used in clinic on obesity for centuries as in “QianJinFang”
(Prescriptions Worth Thousands Gold). Though at that
time the disease is not called as hyperlipidemia, but recent
research has conﬁrmed that those herbs have signiﬁcant
eﬀect on lowing serum cholesterol levels [11–15].
This study aims to examine the underlying mechanisms
of the lipid-lowering role of JZN and compare how its four
main components contribute to this function. Cholesterol
metabolism after drug treatment was examined by analyz-
ing the expression of LDL-R, HMG-CoAR, CYP7A1, and
ACAT2.
2.MaterialsandMethods
2.1. Animals and Cell Lines. Adult laboratory beagles
weighted between 10±1kg were provided by Beijing TongLi
Laboratory Animal Culture Company (Beijing, China). Liver
cell Bel-7402 was provided by Institute of Basic Medical
Sciences of Chinese Academy of Medical Sciences (Beijing,
China). After thaw, Bel-7402cells were ﬁrst cultured at
37◦Ci naC O 2 incubator in RPMI-1640 culture solution
containing10%fetalbovineserum,100U/mLpenicillin,and
100μg/mL streptomycin.
2.2. Preparation of JZN Extracts and the Four Components.
Fleeceﬂowerrootistheprocessedproductofthedriedrootof
polygonum multiﬂorum thunb. Folium nelumbinis is dried
leaf of nelumbo nucifera gaertn. Fructus crataegi and semen
cassiae are dried mature fruits of Crataegus pinnatiﬁda Bge.
v a r .m a j o rN .E .B r .a n dC a s s i ao b t u s i f o l i aL . ,r e s p e c t i v e l y .
All were purchased from Beijing TongRenTang Inc. (Beijing,
China) and authenticated by Professor Guijun Zhang from
Beijing University of Chinese Medicine.
Fleeceﬂower root (25g) and folium nelumbinis (75g)
were mixed and 25-fold of 50% ethanol was added. The
mixture was heated and reﬂuxed for 1.5h. Then, ethanol
extractwasswilledandtheresidueswereﬁlteredanddistilled
twice. The three extracts were combined and concentrated
into ointment, which was named as whole solid I. Fructus
crataegi (500g) and semen cassiae (25g) were mixed and
7-fold of water was added. The mixture was heated and
reﬂuxed for 2h. Then, the liquid extract was swilled and the
residues were ﬁltered and distilled. The two liquid extracts
were combined and concentrated into ointment, which was
named as whole solid II. The two whole solids were mixed
and then dried using decompression drying method at 50◦C.
Hyperin (from ShanZha) and stilbene glycoside (from
ShouWu)weredissolvedinsterilizedwater.Nuciferine(from
HeYe) was dissolved in hydrochloric acid and then the pH
was adjusted to 7.0 by sodium hydroxide. Chrysophanol and
Atorvastatin were dissolved in DMSO.Evidence-Based Complementary and Alternative Medicine 3
2.3. Preparation of JNZ-Containing Serum. To establish a
beagle model of hyperlipidemia, beagles were adaptively fed
for one week and then fed with high-fat feed for two months.
The fat feed was composed of 88% of usualfeed, 10% of lard,
and2%ofcholesterol.Beagleswithhyperlipidemiawerethen
fasted for 12h and fed with 0.4g/kg of JZN extract. 10mL of
veinbloodwaswithdrawnfromthebacklimbofbeaglesafter
0, 1, 2, 4, and 6h. The blood was centrifuged at 3000r/min
for 10min to obtain serums, which were heat-inactivated
for 30min at 56◦C and ﬁltered through 0.22μmm i c r o p o r e
membrane. The concentration of serum LDL was measured
using chemically selective inhibition method.
2.4. Isolation of LDL from Human Serum. The human serum
was collected and centrifuged with gradient solution in a
density of 1.0, 1.1, and 1.3 at 4500r/min for 10min. The
yellow lipid in the center of the solution was extracted as
LDL. After a 48-h dialysis in the dialysate, which contains
0.02M Tris, 0.01% EDTA, and 0.9% NaCl, pH 7.4, the
isolated LDL was kept at 4◦C. The separation of LDL
was conﬁrmed by gelose gel electrophoresis with oil red
O staining. LDL concentration was determined by the
bicinchoninic acid method.
2.5. Stimulation of Bel-7402 Cells with JZN-Containing
Serum. Bel-7402cells were cultured in 6-well plates at 3 ∗
105 cells per mL in 10% 1640 culture media. Alternatively,
after cells became 80% conﬂuent, the 10% 1640 media
were replaced by serum-free 1640 media. After starvation
for 24h to synchronize cells to the G0 phase, the serum-
free media were replaced with 1mL of 1640 culture media
containing 10% JZN-containing serum from diﬀerent time
points. Isolated human LDL was added to the culture media
to make the ﬁnal LDL concentration in the media equal to
theLDLconcentrationsinJZN-containingserumatdiﬀerent
time points.
2.6. Stimulation of Bel-7402 Cells with Four Components
of JZN. Bel-7402cells in logarithmic growth were cultured
in 35mm or 100mm ﬂasks at 3 ∗ 105 cells per mL and
starved in serum-free 1640 culture media for 24h. After
cells became 80% conﬂuent, they were treated with the four
components of JZN or Atorvastatin. The eﬀects of each
component were examined at three diﬀerent concentrations:
the low, medium, and high levels. The three concentrations
of stilbene glycoside, nuciferine, and chrysophanol were
1, 10, and 100μM. The three concentrations of hyperin
were 0.1, 1, and 10μM, respectively. The concentration of
Atorvastatin was 10μM. The drugs, after incubated in the
CO2 i n c u b a t o rw i t h1 0 %B S Af o r2h ,w e r ea d d e dt oc e l l sf o r
24h.
2.7. RT-PCR. Total RNA was extracted from drug-
stimulated Bel-7402cells using Trizol one-step method
and then reverse-transcribed into cDNA using AMV
Reverse Transcriptase. RT-PCR was conducted by the
CYBR green method using following primers (Beijing
Bioko Biotechnology Company, Beijing, China). β-Actin: F:
5 -GGCATCCTCACCCTGAAGTA-3 ;R :5  -GGGGTGTTG-
AAGGTCTCAAA-3 . LDL-R: F: 5 -GCTTGTCTGTCACCT-
GCAAA-3 ;R:5  -AACTGCCGAGAGATGCACTT-3 .HMG-
C o A R :F :5  -CTGGGAGCATAGGAGGCTAC-3 ;R :5  -CCA-
CCCACCGTTCCTATCTC-3 .C Y P 7 A 1 :F :5  -GTCTTTCC-
AGCCCTGGTAGC-3 ;R :5  -GAGGACCACGAGGTGTG-
TCT-3 .A C A T 2 :F :5  -CAAGGAGGTGAAGGACAAGC-3 ;
R: 5 -ATTGGACATGCTCTCCATCC-3 .P C Rr e a c t i o n sw e r e
as follows: one cycle of 5min at 95◦C; 35 cycles of 1min at
94◦C, 45s at 60◦C, and 1min at 72◦C; ﬁnal extension of
10min at 72◦C.
2.8. Western Blot. Equal amount of protein (50μg) was
loaded onto each lane for SDS-PAGE and transferred to
membranes. Membranes were ﬁrst stained with XXX pri-
mary antibodies, then with horseradish peroxidase-linked
secondary antibodies, and developed with a ECL kit (Amer-
sham, UK). Films were scanned and band intensity was
quantiﬁed by ImageMaster Total Lab 1.0.
2.9. Flow Cytometry. Cells from the high-dosage group of
stilbene glycoside treatmentwerewashed twice with PBSand
then once with serum-free medium. Cells were incubated
for 1h in serum-free medium containing 2% BSA and then
washed with 0.5% BSA. For examining surface expression
of LDL-R, cells were incubated with FITC-conjugated anti-
LDL-R primary antibody and then analyzed by ﬂow cytom-
etry. For analyzing LDL binding and internalization, cells
were incubated with 2μL DIL-LDL for 1h at 4◦Ca n d
37◦C, respectively, and then washed and analyzed by ﬂow
cytometry.
3. Results
3.1. Eﬀects of JZN-Containing Serum on Cholesterol
Metabolism in Liver Cells. We ﬁrst established a beagle
model of hyperlipidemia, fed these beagles with JZN extract,
and collected their serum after 0, 1, 2, 4, and 6h. In
Bel-7402cells, 10% of JZN-containing serum from these
beagles signiﬁcantly increased the mRNA expression of
LDL-R, HMG-CoAR, and CYP7A1 after X h stimulation
(P<0.05, Table 1). The maximum eﬀect was induced by
1-h JZN-containing serum for LDL-R and HMG-CoAR
and by 2-h JZN-containing serum for CYP7A1 (Table 1). In
contrast, 1-h JZN-containing serum signiﬁcantly decreased
the mRNA expression of ACAT2 (Table 1).
3.2. Eﬀects of Four Components of JZN on Cholesterol
Metabolism in Liver Cells (mRNA Analysis). As a positive
control, we ﬁrst tested the eﬀects of Atorvastatin on
cholesterolmetabolism.Atorvastatintreatmentincreasedthe
mRNA expression of LDL-R, HMG-CoAR, and CYP7A1
and decreased the mRNA expression of ACAT2 (P<0.05,
Tables 2, 3, 4,a n d5).
Stilbene glycoside and nuciferine showed a similar pat-
tern of inﬂuence on cholesterol metabolism in liver cells.
Compared with the no-drug control group, mRNA expres-
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Table 1: The eﬀects of JZN-containing serum on cholesterol metabolism in liver cells.
Time point LDL-R HMG-CoAR CYP7A1 ACAT2
0h 1 1 1 1
1h 3.66±0.07
∗∗ 1.95 ±0.04∗ 1.74±0.03∗∗ 0.73 ± 0.07
2h 1.48 ±0.03∗ 0.97 ±0.11 1.98±0.06
∗∗ 0.87 ±0.21
4h 1.11 ±0.08 1.27 ±0.06
∗ 1.26 ±0.08
∗ 1.2 ±0.04
6h 0.87 ±0.12 0.94 ±0.09 0.73 ±0.07 0.99 ±0.09
Note: comparison with 0-h time point, ∗P<0.05, ∗∗P<0.01.
Table 2: The eﬀects of stilbene glycoside treatment on cholesterol metabolism in liver cells (mRNA analysis).
Treatment LDL-R HMG-CoAR CYP7A1 ACAT2
No stilbene glycoside 0.65 ±0.60 0.70 ±0.05 0.24 ±0.05 0.98 ±0.06
Stilbene glycoside: low dose 0.74 ±0.04∗ 0.90 ±0.08∗∗ 0.21 ±0.07 1.07 ±0.07
Stilbene glycoside: medium dose 0.99 ±0.12∗∗ 0.87 ±0.12∗∗ 0.19 ±0.05 0.85 ±0.22∗∗
Stilbene glycoside: high dose 1.26 ±0.36∗∗ 1.02 ±0.19∗∗ 0.26 ±0.09 0.87 ±0.32∗∗
Atorvastatin 1.15 ±0.14∗∗ 1.03 ±0.24∗∗ 0.53 ±0.04 0.65 ± 0.08∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 3: The eﬀects of nuciferine treatment on cholesterol metabolism in liver cells (mRNA analysis).
Treatment LDL-R HMG-CoAR CYP7A1 ACAT2
N o n u c i f e r i n e 1111
Nuciferine: low dose 1.86 ±0.84∗∗ 2.18 ±0.26∗∗ 0.94 ±0.17 0.97 ±0.24
Nuciferine: medium dose 2.95 ±0.25∗∗ 2.58 ±0.14∗∗ 0.93 ±0.26 0.95 ±0.28
Nuciferine: high dose 3.57 ±1.01∗∗ 2.96 ±0.25∗∗ 1.15 ±0.31 0.78 ±0.19∗∗
Atorvastatin 5.83 ±0.19∗∗ 6.58 ±0.28∗∗ 1.29 ±0.12∗ 0.49 ±0.33∗∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 4: The eﬀects of hyperin on cholesterol metabolism in liver cells (mRNA analysis).
Treatment LDL-R HMG-CoAR CYP7A1 ACAT2
No hyperin 1 1 1 1
Hyperin: low dose 1.64 ±0.27∗ 2.18 ±0.19∗∗ 1.21 ±0.18∗ 1.03 ±0.21
Hyperin: medium dose 2.82 ±0.36∗∗ 3.29 ±0.31∗∗ 1.57 ±0.22∗∗ 0.65 ±0.36∗∗
Hyperin: high dose 2.66 ±0.24∗∗ 2.87 ±0.25∗∗ 1.06 ±0.19 0.61 ±0.29∗∗
Atorvastatin 5.82 ±0.27∗∗ 6.48 ±0.29∗∗ 1.29 ±0.45∗∗ 0.49 ±0.38∗∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
increased after stilbene glycoside or nuciferine stimulation
(P<0.05, Tables 2 and 3). Stimulation with stilbene
glycoside (median and high doses) or nuciferine (high dose)
signiﬁcantly decreased mRNA expression of ACAT2 (P<
0.01, Tables 2 and 3). CYP7A1 mRNA expression was not
aﬀectedbystilbeneglycosideornuciferine(P>0.05,Tables2
and 3).
Hyperin and chrysophanol showed similar inﬂuence on
cholesterol metabolism in liver cells. Compared with the
control group, stimulation with hyperin or chrysophanol
also signiﬁcantly increased the mRNA expression of LDL-
R and HMG-CoAR (P<0.05, Tables 4 and 5). Diﬀerent
from stilbene glycoside and nuciferine, hyperin (low and
medium doses) and chrysophanol (medium and high doses)
signiﬁcantly increased Cyp7A1 mRNA levels (P<0.05,
Tables 4 and 5). Expression of ACAT2 mRNA was signif-
icantly reduced by hyperin (medium and high doses) or
chrysophanol (all three doses) treatment (P<0.01, Tables 4
and 5).
3.3. Eﬀects of Four Components of JZN on Cholesterol
Metabolism in Liver Cells (Protein Analysis). Atorvastatin
and the four components of JZN showed similar aﬀects. Pro-
tein expression of LDL-R and HMG-CoAR was signiﬁcantly
increasedunderalltreatments(P<0.01,Tables6,7,8,and9,
Figures 1, 2, 3,a n d4). In contrast, ACAT2 protein expression
was signiﬁcantly reduced under all treatments (P<0.01
except for low dose of stilbene glycoside, Tables 6, 7, 8,a n d9,
Figures 1, 2, 3,a n d4).Evidence-Based Complementary and Alternative Medicine 5
Table 5: The eﬀects of chrysophanol treatment on cholesterol metabolism in liver cells (mRNA analysis).
Treatment LDL-R HMG-CoAR CYP7A1 ACAT2
No chrysophanol 0.42 ±0.07 0.41 ±0.11 0.28 ±0.07 0.64 ±0.15
Chrysophanol: low dose 0.62 ±0.04∗ 0.54 ±0.19∗ 0.31 ±0.12 0.42 ±0.16∗∗
Chrysophanol: medium dose 0.75 ±0.03∗∗ 0.72 ±0.14∗∗ 0.33 ±0.09∗ 0.37 ±0.18∗∗
Chrysophanol: high dose 0.88 ±0.09∗∗ 0.81 ±0.22∗∗ 0.37 ±0.14∗∗ 0.30 ±0.07∗∗
Atorvastatin 0.93 ±0.07∗∗ 0.86 ±0.18∗∗ 0.49 ±0.13∗ 0.31 ±0.13∗∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 6: The eﬀects of stilbene glycoside treatment on cholesterol metabolism in liver cells (protein analysis).
Treatment LDL-R HMG-CoAR ACAT2
No stilbene glycoside 0.32 ±0.02 0.38 ±0.05 1.24 ±0.04
Stilbene glycoside: low dose 0.41 ±0.06∗∗ 0.44 ±0.07 1.26 ±0.23
Stilbene glycoside: medium dose 1.09 ±0.05∗∗ 0.96 ±0.21∗∗ 1.07 ±0.25
Stilbene glycoside: high dose 1.27 ±0.07∗∗ 1.20 ±0.24∗∗ 1.02 ±0.31
Atorvastatin 1.58 ±0.03∗∗ 1.77 ±0.08∗∗ 0.51 ±0.06∗∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 7: The eﬀects of nuciferine treatment on cholesterol metabolism in liver cells (protein analysis).
Treatment LDL-R HMG-CoAR ACAT2
No nuciferine 0.25 ±0.02 0.26 ±0.03 1.23 ±0.02
Nuciferine: low dose 0.60 ±0.11∗∗ 0.48 ±0.16∗∗ 0.76 ±0.16∗∗
Nuciferine: medium dose 0.91 ±0.14∗∗ 0.53 ±0.14∗∗ 0.87 ±0.25∗∗
Nuciferine: high dose 0.98 ±0.26∗∗ 0.51 ±0.23∗ 0.71 ±0.18∗∗
Atorvastatin 1.68 ±0.21∗∗ 0.68 ±0.19∗∗ 0.58 ±0.22∗∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 8: The eﬀects of hyperin on cholesterol metabolism in liver cells (protein analysis).
Treatment LDL-R HMG-CoAR ACAT2
No hyperin 0.17 ±0.05 0.73 ±0.03 0.74 ±0.06
Hyperin: low dose 0.33 ±0.08∗∗ 1.41 ±0.07∗∗ 0.53 ±0.02∗∗
Hyperin: medium dose 0.29 ± 0.11∗ 1.47 ±0.16∗∗ 0.48 ±0.15∗∗
Hyperin: high dose 0.62 ±0.09∗∗ 1.54 ±0.07∗∗ 0.57 ± 0.16∗
Atorvastatin 0.86 ±0.13∗∗ 2.69 ±0.25∗∗ 0.52 ± 0.18∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.
Table 9: The eﬀects of chrysophanol treatment on cholesterol metabolism in liver cells (protein analysis).
Treatment LDL-R HMG-CoAR ACAT2
No chrysophanol 0.23 ±0.08 0.25 ±0.04 0.36 ±0.12
Chrysophanol: low dose 0.38 ± 0.11∗ 0.27 ±0.17 0.32 ±0.06
Chrysophanol: medium dose 0.61 ±0.15∗∗ 0.29 ±0.12 0.21 ± 0.11∗
Chrysophanol: high dose 0.95 ±0.13∗∗ 0.51 ±0.14∗∗ 0.19 ± 0.09∗
Atorvastatin 1.61 ±0.26∗∗ 0.97 ±0.28∗∗ 0.22 ± 0.07∗
Note: comparison with no-drug control group, ∗P<0.05, ∗∗P<0.01.6 Evidence-Based Complementary and Alternative Medicine
3.4. Eﬀects of Stilbene Glycoside Treatment on Surface Level
of LDL-R. Our ﬂow cytometry analysis showed that similar
to Atorvastatin, stilbene glycoside signiﬁcantly increased
surface expression of LDL-R, as well as binding and inter-
nalization of LDL (P<0.01, Table 10 and Figure 5).
4. Discussion
Hyperlipidemia causes progressive atherosclerosis, which is
the major cause of cardiovascular diseases. Clinically, 80%
to 90% of acute coronary events are triggered by sudden
collapse of atherosclerotic plaques [16]. The stability of
plaques is related to lipid content: the higher the lipid
content, the lower the stability. In addition, hyperlipidemia
is also an important risk factor for hypertension, impaired
glucose tolerance, and diabetes. Hyperlipidemia can also
leadtohepaticadiposeinﬁltration,cirrhosis,gallstones,pan-
creatitis, fundus hemorrhage, blindness, peripheral vascular
disease, claudication, and hyperuricemia. Some primary and
familial hyperlipidemia may also cause tendon-like, nodular,
palm print, periorbital xanthomas, and arcus juvenilis.
Therefore, hyperlipidemia treatment has become a hot topic
in recent years.
Many diﬀerent types of lipid-regulating drugs, including
resins, statins, niacin, and unsaturated fatty acid lipid-
regulating drugs, have been developed. However, most of
thesedrugsonlyfocusononestepofcholesterolmetabolism.
Few currently available drugs target cholesterol synthesis,
absorption, modiﬁcation, and conversion all together. In
addition, most lipid-regulating drugs cause serious side
eﬀects, including gastrointestinal problems and liver and
kidney dysfunction.
Numerous lipid-lowering formulae have been recorded
in TCM. However, their application has been limited due
to a lack of thorough understanding of both their eﬀective
ingredients and underlying mechanisms. There is also no
standardized quality control in drug preparation. Therefore,
it is imperative to examine active ingredients from known
lipid-lowering TCM for their pharmacological eﬀects. This
h a sb e e np r o v e nt ob ea ne ﬀective strategy to develop
novel, more eﬃcacious lipid-regulating drugs with fewer
side eﬀects. It has been reported that the activity of LDL-
R can be enhanced by tea polyphenol as well as the water-
solubleandethanol-solubleextractsofturmeric[17,18].The
expression of LDL-R in rat liver is increased by guanxinkang
decoction that is composed of astragalus, trichosanthes,
scalion white, and salvia miltiorrhiza [19, 20]. The expres-
sion of LDL-R and high-density lipoprotein receptor is
also increased by tiaogandaozhuo decoction consisting of
processed polygonum multiﬂorum, radix bupleuri, cassia,
alisma, salvia miltiorrhiza, fructus leonuri, tumeric, cattail
pollen, and so forth [21]. Up to now, studies in this area
have mainly focused on regulation on LDL. The current
study aims to extend research on lipid-lowering TCM to
cholesterolabsorption,synthesis,conversion,andothersteps
in cholesterol metabolism.
JZN shows signiﬁcant cholesterol-lowering eﬀects. Poly-
gonum multiﬂorum thunb, hawthorn, lotus leaf, and cassia
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Figure 1: LDL-R, HMG-CoAR, and ACAT2 protein expression
under stilbene glycoside treatment. Notes: Lane 1: no-drug control;
2: low dose of stilbene glycoside; 3: medium dose of stilbene
glycoside; 4: high dose of stilbene glycoside; 5: Atorvastatin.
seed are all frequently used as lipid-lowering TCM. Total
glycoside from polygonum multiﬂorum thunb shows signif-
icant lipid-lowering and antioxidant eﬀects [22]. The total
cholesterol and triglyceride values in hyperlipidemic mice
are signiﬁcantly reduced by hawthorn ﬂavonoids of diﬀerent
purity[23].Furthermore,diﬀerentproportionsofcassiaseed
extract and hawthorn extract have been shown to reduce the
levels of total cholesterol, triglyceride, LDL-cholesterol, and
Apo B in hyperlipidemic mice [24].
However, the current understanding of JZN or its
four major components is still far from satisfactory. Stil-
bene glycoside has been shown to exert neuroprotectiv-
ity, antioxidation, and lipid-lowering eﬀects [25, 26]. But
its mechanisms remain unclear. Pharmacological studies
of hyperoside mainly focus on analgesia and the pro-
tection of cardiovascular system whereas its eﬀect on
hyperlipidemia has not been reported [27]. The role of
nuciferine has been studied in models of obese hyperlipi-
demic rats [28]. The function of chrysophanol is hardly
known.
In the current study, we ﬁrst examined the role of
JZN in lipid metabolism in liver cells. It is worth noting
that for a long time, a routine TCM pharmacological
experiment is conducted as follows: ingredients of TCM
are ﬁrst extracted and separated and then added directly
to an in vitro system (e.g., cell culture), and the eﬀects of
various ingredients are added to illustrate the eﬀectiveness
of a TCM recipe. Research on pharmacodynamic material
basis and mechanism of Chinese herbal compound is still
the diﬃcult and hot spot in Chinese medicine research.
Study on serum pharmacochemistry of herbal compoundEvidence-Based Complementary and Alternative Medicine 7
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Figure 2: LDL-R, HMG-CoAR, and ACAT2 protein expression
under nuciferine treatment. Notes: Lane 1: no-drug control; 2: low
dose of nuciferine; 3: medium dose of nuciferine; 4: high dose of
nuciferine; 5: Atorvastatin.
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Figure 3: LDL-R, HMG-CoAR, and ACAT2 protein expression
under hyperin treatment. Notes: Lane 1: no-drug control; 2: low
doseofhyperin;3:mediumdoseofhyperin;4:highdoseofhyperin;
5: Atorvastatin.
directly from the components that absorbed into the body
directly narrows the scope of constituent research and
provides a new way for herbal compound research. But it
is still at the exploratory stage, there are many diﬃculties
in practical research. In our experiment, we found that the
serum medicine concentration is low in case of Chinese
herbal compound taken by oral and due to the experimental
conditionsandtechnicallimitations,whichisstillachallenge
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Figure 4: LDL-R, HMG-CoAR, and ACAT2 protein expression
under chrysophanol treatment. Notes: Lane 1: No-drug control; 2:
Low dose of chrysophanol; 3: Medium dose of chrysophanol; 4:
High dose of chrysophanol; 5: Atorvastatin.
in drug-testing. However, this method neglects the following
characteristicsofTCM:(1)inmostcases,TCMistakenorally
and thus the ingredients entering blood after metabolism in
the gastrointestinal tract and liver may diﬀer signiﬁcantly
from the original ingredients; (2) the components of TCM
may interact and cross-talk and therefore, the overall eﬀect
of TCM does not equal the sum of the eﬀects of individual
ingredients; (3) the physical and chemical properties of TCM
components in extracts are not constant from study to study,
making it diﬃcult to reach consensus conclusions. Based on
the above considerations, Shinichi Tashiro proposed using
medicine-containing serum for in vitro pharmacological
studies [29]. Chinese herbal compound exerts its pharmaco-
dynamicseﬀectafteroraladministrationandgastrointestinal
absorption into blood and body interactions. Applying
serum pharmacology method, the use of the medicine-
containing serum in vitro experiment is more closely related
to the real process of exerting pharmacological eﬀects in
vivo environment. This method provides a new way for
pharmacodynamic material basis research of Chinese herbal
compound.
Medicine-containing serum is collected from animals
fed with TCM after a certain period of time. This TCM
serum method mimics the genuine route of TCM to
take eﬀects in vivo and thus provides more information
about the pharmacological role of TCM. We adopted this
method and demonstrated that in liver Bel-7402cells, 10%
JZN-containing serum signiﬁcantly increases the mRNA
expression of LDL-R, HMG-CoAR, and CYP7A1. Since it
is crucial to observe the eﬃcacy of diﬀerent time points of
JZN-containing serum to further determine which point in
time to extract and separate the serum-containing material.8 Evidence-Based Complementary and Alternative Medicine
Table 10: The eﬀects of stilbene glycoside treatment on the surface expression of LDL-R.
Treatment LDL-R
Expression LDL Binding LDL Internalization
No-drug 11.68 ±3.72 18.47 ± 2.34 7.94 ±2.95
Stilbene glycoside 24.42 ±5.21∗∗ 34.06 ±6.29∗∗ 81.01 ±5.22∗∗
Atorvastatin 51.07 ±6.34∗∗ 109.88±10.60∗∗ 135.23 ±17.63∗∗
Note: comparison with no-drug control group, ∗∗P<0.01.
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Figure 5: The eﬀects of stilbene glycoside treatment on the surface expression of LDL-R. Treatment of stilbene glycoside or atorvastatin
increased LDL-R surface expression as well as LDL binding and internalization.
According to the reported drug metabolism in vivo,a b o u t
80 percent reported that the process of drug metabolism is
within two hours. So our experiments set 0, 1, 2, 4, 6 hours
after administration as ﬁve time points. However, due to the
complexity of endogenous components of the serum itself, if
we use blank serum as a control, it will be another diﬃculty
in determining the time points of blank serum. In this study,
we use the LDL concentration in the medium calibration
to ensure a consistent amount of stimulation.The maximum
induction eﬀect is achieved by 1-h JZN-containing serum for
the former two molecules and by 2-h JZN-containing serum
for the last one. JZN-containing serum collected after 1h
signiﬁcantly reduces the mRNA expression of ACAT2. The
diﬀerent eﬀects at diﬀerent time points may reﬂect changes
in eﬀective ingredients of the plasma drug following drug
uptake.
Cholesterol absorption and synthesis are negatively reg-
ulated by their end products. When cholesterol levels are
low (e.g., when treated with Atorvastatin), the transcription
factor SREBP is activated and triggers the transcription of
LDL-R and HMG-CoAR [30]. The dominant regulator of
CYP7A1 transcription is liver X receptor α (LXRα), a sterol-
dependent nuclear receptor [31, 32]. The LXR response
element DR4 has been found to interact with the promoter
region of CYP7A1 in human and mice [33]. The current
study suggested that JZN-containing serum increases the
mRNA levels of LDL-R, HMG-CoAR, and CYP7A1 through
the SREBP and LXR transcription pathways.
In this study, all four major components of JZN,
stilbene glycoside, nuciferine, hyperin, and chrysophanol,
signiﬁcantly increase the mRNA and protein expression
of LDL-R and HMG-CoAR and signiﬁcantly reduce the
mRNA and protein expression of ACAT2. Hyperin and
chrysophanol also signiﬁcantly increase the mRNA expres-
sion of CYP7A1. In addition, stilbene glycoside increases
the surface expression of LDL-R as well as the surface
binding and internalization of LDL. Our results showed
that the components of JZN may exert lipid-lowering eﬀects
by increasing the surface expression and activity of LDL-
R in liver cells, inhibiting intracellular cholesterol synthesis,
increasing the conversion of cholesterol into bile acid, and
reducing ACAT2-mediated cholesterol esteriﬁcation. Our
study suggested that these four components of JZN are
promising candidates for developing new medications to
treat hyperlipidemia and related diseases.
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